A research partnership expanding Reflector Bio’s validated case studies into additional therapeutic areas where phenotypic screening is indicated. Announcement forthcoming.
Founder and CEO Yuge Ji, PhD, presents at the SCbio Drive Life Sciences Demo Day as part of the Drive Accelerator Fall 2025 cohort.
Founder and CEO Yuge Ji, PhD, addresses the role of AI in early-stage drug discovery at the NGEN Lab-to-Startup Conference.
A perturbation analysis framework co-developed by the Reflector Bio team was published in Nature Methods, establishing standardized tooling for quantifying treatment effects across large-scale perturbation screens.
Reflector Bio was selected for the PharmStars Fall 2025 cohort.
Reflector Bio was selected for the Techstars NYC Fall 2025 cohort.
Founder and CEO Yuge Ji, PhD, presents at the MassBio Align Summit as part of the Drive Accelerator Fall 2025 cohort.
Reflector Bio was selected to the inaugural TechBio cohort of the Drive Accelerator, organized by MassBio in partnership with SCbio.
Reflector Bio’s scientific advisor, Prof. Fabian Theis was awarded the ISCB Innovator Award at ISMB/ECCB 2025. His keynote covered perturbation modelling and generative frameworks for predicting cellular response.
Reflector Bio’s parent lab, led by Prof. Fabian Theis, joined the Cancer Plasticity Atlas, led by the Wellcome Sanger Institute. The Cancer Plasticity Atlas is an international consortium mapping cancer cell state transitions and therapeutic response.
Receive occasional updates on publications, partnerships and platform developments
Tell us about your biology. We will tell you whether our model already covers it or what it would take to get there.